ReviewLupus science & medicine2022
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.
Review in Lupus science & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07056621 (Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study
Who cites it
25 citing papers in PubMed.
- Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.Annals of the rheumatic diseases · 2024Trial
- Clinical correlates and predictors of thrombocytopenia in childhood-onset systemic lupus erythematosus: a retrospective cohort study.Pediatric rheumatology online journal · 2026Article
- Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification.Journal of clinical medicine · 2026Review
- Article
- Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Practical insights for the clinical implementation of the EULAR recommendations for patients with systemic lupus erythematosus.RMD open · 2025Article
- Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management.Kidney international reports · 2025Review
- Disease Modification in Psoriasis: Future Prospects for Long-Term Remission.American journal of clinical dermatology · 2025Review
- Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents.Rheumatology and therapy · 2025Review
- Disease-modifying anti-nephropathic drugs (DMANDs)-a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes.Rheumatology (Oxford, England) · 2025Article
- Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from Sweden.Lupus science & medicine · 2025Article
- Animal models of neuropsychiatric systemic lupus erythematosus: deciphering the complexity and guiding therapeutic development.Autoimmunity · 2024Review
- The Potential Use of Arsenic Trioxide in the Treatment of Systemic Lupus Erythematosus.International journal of molecular sciences · 2024Review
- Unlocking the role of Smith-specific regulatory T-cells: a paradigm shift in autoimmune therapy.Annals of medicine and surgery (2012) · 2024Article
- Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.Lupus science & medicine · 2024Review
- Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2024Article
- CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.Frontiers in immunology · 2024Review
- Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.Frontiers in immunology · 2024Observational
- Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications.Genome medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists for SLE.We reviewed established definitions of disease modification in other conditions and identified a meaningful effect on 'disease manifestations' (ie, signs, symptoms and patient-reported outcomes) and on 'disease outcomes' (eg, long-term remission or progression of damage) as the key principles of disease modification, indicating a positive effect on the natural course of the disease. Based on these findings and the treatment goals and outcome measures for SLE, including lupus nephritis, we suggest a definition of disease modification based on disease activity indices and organ damage outcomes, with the latter as a key anchor. A set of evaluation criteria is also suggested.Establishing a definition of disease modification in SLE will clarify which treatments can be considered disease modifying, provide an opportunity to harmonise future clinical trial outcomes and enable comparison between therapies, all of which could ultimately help to improve patient outcomes. This publication seeks to catalyse further discussion and provide a framework to develop an accepted definition of disease modification in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.